NCT02981628 2026-02-23Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic LeukemiaChildren's Oncology GroupPhase 2 Recruiting80 enrolled 1 FDA
NCT03504397 2026-02-13SpotlightAstellas Pharma IncPhase 3 Active not recruiting565 enrolled 63 charts 1 FDA
NCT02003222 2025-11-28Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)Phase 3 Active not recruiting488 enrolled 13 charts 1 FDA
NCT04008030 2025-10-03CheckMate 8HWBristol-Myers SquibbPhase 3 Active not recruiting839 enrolled 22 charts 1 FDA
NCT04607421 2025-08-14A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal CancerPfizerPhase 3 Active not recruiting831 enrolled 2 FDA
NCT02872116 2025-08-07CheckMate649Bristol-Myers SquibbPhase 3 Completed2,031 enrolled 19 charts 1 FDA